Indigo Diabetes NV
Indigo is a pioneering developer of medical solutions using nanophotonics, focused on creating the world’s first invisible continuous multi-metabolite monitoring (CMM®) system for people living with chronic diseases. The company aims to improve outcomes, lower costs, and enhance quality of life through innovative high-tech solutions for advanced biomarker sensing. Founded in 2016 and based in Ghent, Belgium, Indigo leverages groundbreaking photonics technology to transform chronic disease management.
Industries
Nr. of Employees
small (1-50)
Indigo Diabetes NV
Patents
Personal health monitoring system, multiple user health monitoring system, and method
US-11992310-B2
View Details
Personal health monitoring system, multiple user health monitoring system, and method
US-11992310-B2
View DetailsProducts
Implantable continuous multi-metabolite sensor
A subcutaneous, miniaturized optical sensor designed to continuously measure multiple metabolites (initially glucose, ketone and lactate) via on‑chip spectroscopy, transmit data wirelessly to mobile devices, and operate on a rechargeable battery for extended periods.
Implantable continuous multi-metabolite sensor
A subcutaneous, miniaturized optical sensor designed to continuously measure multiple metabolites (initially glucose, ketone and lactate) via on‑chip spectroscopy, transmit data wirelessly to mobile devices, and operate on a rechargeable battery for extended periods.
Services
Design and execution of early feasibility and multicentre clinical trials to evaluate safety, tissue integration, stability and performance of implanted multi‑metabolite sensors; includes protocolized comparator sampling and performance challenge testing.
Research and development activities focused on validating capex‑light CMOS‑compatible manufacturing routes for miniaturized spectrometer chips to enable scalable production.
Development of compliant software strategies and mobile application connectivity for real‑time display, warning generation and sharing of sensor-derived metabolite data; emphasis on secure and regulatory‑compliant data handling.
Design and execution of early feasibility and multicentre clinical trials to evaluate safety, tissue integration, stability and performance of implanted multi‑metabolite sensors; includes protocolized comparator sampling and performance challenge testing.
Research and development activities focused on validating capex‑light CMOS‑compatible manufacturing routes for miniaturized spectrometer chips to enable scalable production.
Development of compliant software strategies and mobile application connectivity for real‑time display, warning generation and sharing of sensor-derived metabolite data; emphasis on secure and regulatory‑compliant data handling.
Expertise Areas
- Continuous multi-metabolite sensing
- Implantable medical device development
- Silicon photonics and nanophotonics
- Clinical trial design and execution for implantable devices
Key Technologies
- Silicon photonics
- Miniaturized spectrometer-on-chip
- Label-free optical absorption spectroscopy
- Implantable subcutaneous sensors
News & Updates
Indigo Diabetes NV has been selected as one of just 65 startups to join the prestigious 2025 MedTech Innovator Accelerator Cohort, chosen from nearly 1,500 applicants, placing it among the top 4% of emerging medtech.
Indigo was recognized as a 'Key Innovator' by the European Commission's Innovation Radar for its groundbreaking work on the Multi-Metabolite Sensor, developed within the MuSiC4Diabetes project.
Indigo announced the successful completion of the SHINE Study, a feasibility trial of their implantable continuous multi-metabolite monitor designed to measure glucose, ketone, and lactate concentrations in real time.
Indigo Diabetes NV has been selected as one of just 65 startups to join the prestigious 2025 MedTech Innovator Accelerator Cohort, chosen from nearly 1,500 applicants, placing it among the top 4% of emerging medtech.
Indigo was recognized as a 'Key Innovator' by the European Commission's Innovation Radar for its groundbreaking work on the Multi-Metabolite Sensor, developed within the MuSiC4Diabetes project.
Indigo announced the successful completion of the SHINE Study, a feasibility trial of their implantable continuous multi-metabolite monitor designed to measure glucose, ketone, and lactate concentrations in real time.